Toll-like receptors (TLRs) represent the major pathway by which microorganisms interact with host cells. They are a family of highly conserved pattern-recognition receptors that recognize distinct pathogen-associated molecular patterns that are conserved in specific classes of microorganisms 1 . The human TLR family consists of at least ten members that can be classified into two different groups on the basis of their cellular location. Intracellular TLRs (TLR3, TLR7, TLR8 and TLR9) recognize nucleic acids; TLR7 and TLR8 recognize singlestranded RNA 2,3 , whereas TLR3 and TLR9 are receptors for doublestranded RNA and double-stranded DNA, respectively. In contrast, cell surface TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6) recognize various components of bacteria 1 . In mice, although TLR7 and TLR8 are expressed at low levels in CD4 + T cells, there are species-specific differences in the recognition of ligands 3 as well as in their functionality. Specifically, mouse TLR7 and human TLR8 mediate species-specific recognition of GU-rich single-stranded RNA. It has been suggested that in contrast to its human TLR counterpart, mouse TLR8 is not functional and TLR7 is the only TLR that recognizes single-stranded RNA 4 . The expression and signaling pathways triggered by stimulation of TLRs have been described in antigen-presenting cells (APCs) in a process that leads to the activation of APCs with the secretion of inflammatory and antiviral cytokines 1, 5 . Although TLR expression has been studied mainly in APCs, several reports have described the expression of TLRs on lymphocytes 6 , and specifically on CD4 + T cells. As with APCs, such studies indicate that the engagement of TLRs acts as a positive costimulatory signal that increases the secretion of proinflammatory cytokines, proliferation and cell survival 7, 8 .
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While TLRs are central to the early host immune response to acute viral infection, more-chronic infectious diseases are characterized by the inability of the host immune system to mount a strong, long-lasting response to the infectious agent. In particular, it has been shown that during infection with RNA viruses such as hepatitis C virus and human immunodeficiency virus type 1 (HIV-1), the immune responses mediated by CD4 + helper T cells and CD8 + cytotoxic T cells determine the outcome of the infection, with chronic infections being correlated with late, transient or narrowly focused responses by CD4 + or CD8 + T cells [9] [10] [11] . Several studies have demonstrated impairment in the activation and/or function of T cells during infection with HIV-1. Specifically, CD4 + T cells from patients chronically infected with HIV-1 display an anergic phenotype with defects in proliferation and the secretion of interleukin 2 (IL-2) and interferon-γ (IFN-γ). The mechanisms by which RNA viruses impair T cell function are not well understood.
Here we describe a previously unrecognized pathway of TLRmediated negative regulation of both the activation and the cytokine production of CD4 + T cells. Engaging TLR7 expressed on CD4 + T cells resulted in complete anergy by inducing intracellular calcium flux, with activation of an anergic gene-expression program dependent on the transcription factor NFATc2 and with subsequent T cell unresponsiveness that was reversed by knockdown of TLR7 with short hairpin RNA (shRNA). In studies of the potential physiological relevance of these findings, we found that knockdown of TLR7 via shRNA decreased the frequency of HIV-1-infected CD4 + T cells in vitro and restored the responsiveness of those HIV-1 + CD4 + T cells in vitro. Our results elucidate a previously unknown function for microbial pattern-recognition receptors in the downregulation of immune responses, inducing anergy by increasing intracellular calcium concentrations and interfering with secondary costimulation signals in the presence of signaling via TLRs 7 .
RESULTS

Inhibition of the activation of CD4 + T cells by TLR7
While investigating a potential costimulatory role for TLRs in CD4 + T cells, we observed that the entry of CD4 + T cells into the cell cycle after crosslinking of the T cell antigen receptor (TCR) with antibody to the invariant signaling protein CD3 (anti-CD3) and crosslinking of the coreceptor CD28 with anti-CD28 was blocked by coengagement of TLR7 (Fig. 1a,b and Supplementary Fig. 1a,b) . Treatment with the synthetic TLR7 agonist imiquimod resulted in considerably less proliferation of CD4 + T cells than that of vehicle-treated control cells, as well as less secretion of IFN-γ and IL-17, in a dose-dependent fashion (Fig. 1c-e and Supplementary Fig. 1c,d ). We observed this inhibitory effect as soon as 12 h after activation, with much less induction of the expression of IL2, IFNG and IL4 after treatment with imiquimod ( Supplementary Fig. 1e) . We assessed the effect of concentrations of up to 15 µg/ml of imiquimod but found no effect on cell viability (data not shown). The diminished proliferation correlated with less secretion of the cytokines IFN-γ, IL-17, IL-2 and IL-4, as measured by enzyme-linked immunosorbent assay (ELISA), at day 3 after stimulation (Fig. 1c) . We confirmed the diminished cytokine secretion at the single-cell level, as the frequency of cytokine-producing cells was also diminished in a dose-dependent manner with increasing doses of imiquimod in culture (Fig. 1d,e) . Furthermore, stimulation of CD4 + T cells in the presence of imiquimod inhibited the expression of activation markers such as CD25, CD69 and CD137, measured 48 h (f) Expression of CD25 (left), CD69 (middle) and CD137 (right) on CD4 + T cells stimulated with anti-CD3 and anti-CD28 in the presence (α-CD3 and α-CD28 + IMQ) or absence (α-CD3 and α-CD28) of imiquimod, and of cells stained with isotype-matched control antibody (Isotype). MFI, mean fluorescence intensity. *P < 0.05, **P < 0.005 and ***P < 0.0005 (paired t-test). Data are representative of eight (a-d) or six (e,f) independent experiments with one donor in each (mean and s.e.m. in b,c,e,f).
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VOLUME 16 NUMBER 1 JANUARY 2015 nature immunology A r t i c l e s after activation (Fig. 1f) . Of note, the effect of imiquimod was not related to the conversion of CD4 + T cells into a population of regulatory T cells (T reg cells), as neither expression of the transcription factor Foxp3 nor secretion of IL-10 was increased in the presence of imiquimod (data not shown). The unresponsive phenotype observed was not due to an indirect effect of TLR7 on T reg cells, as we obtained the same results with a CD4 + T cell population sorted as CD3 + CD4 + or CD4 + CD25 lo CD127 + cells and depleted of T reg cells (data not shown). Only stimulation of TLR9 with the synthetic ligand oligodeoxynucleotide ODN2006 also decreased the frequency of proliferating CD4 + T cells, but it did so to a lesser extent than did stimulation of TLR7 ( Supplementary Fig. 1a,b) . The effect observed was not due to an indirect effect of the triggering of TLR7 on contaminant APCs in the culture, as imiquimod exerted the same effect on T cell clones grown from a single donor (Supplementary Fig. 2) .
To confirm the specificity of our results, we stimulated CD4 + T cells in the presence of other synthetic ligands of TLR7, such as loxoribine, CL264 or gardiquimod (Fig. 2) . The three ligands tested induced a significantly less CD4 + T cell proliferation than did a vehicle control, with gardiquimod and loxoribine inhibiting proliferation to a degree similar to that achieved by imiquimod treatment (Fig. 2a,b) . The secretion of IL-2, IFN-γ, IL-4 and IL-17 was also inhibited after stimulation in the presence of each of the three ligands, as measured by ELISA after 3 d in culture (Fig. 2c) . The specificity of the phenotype observed was further demonstrated by silencing of TLR7 in CD4 + T cells (Fig. 2d) . While control CD4 + T cells transduced with nontargeting shRNA responded to treatment with imiquimod by decreasing their secretion of IFN-γ and IL-2, CD4 + T cells in which TLR7 was silenced that were stimulated with imiquimod produced concentrations of IFN-γ and IL-2 similar to those produced after treatment with vehicle (Fig. 2e) . Both TLR7 and TLR8 are expressed in human CD4 + T cell subpopulations 6, 8 ; however, although reports suggest that both TLR7 and TLR8 recognize single-stranded RNA as their natural ligand in APCs 2,3 , we observed no such effect when we used the TLR8 ligand ssRNA40 (a single-stranded RNA) in the transfection reagent LyoVec in these experiments in parallel with TLR7 ligands (Fig. 2f,g ). Instead, stimulation of T cells in the presence of ssRNA40 significantly increased the production of IFN-γ and inhibited the secretion of IL-4 by CD4 + T cells (Fig. 2g) , with no effect on proliferation (Fig. 2f) . Vehicle alone (LyoVec) did not have any effect on cytokine secretion or proliferation under these experimental conditions (data not shown). We obtained the same results with CL075, another ligand predominantly of TLR8 (data not shown). These data were in agreement with a published report 8 and suggested that despite sharing ligands, the signaling pathways that TLR7 and TLR8 triggered on CD4 + T cells led to different phenotypic outcomes.
Ligation of TLR7 induces the activation and maturation of APCs, with upregulation of activation markers and secretion of proinflammatory cytokines [12] [13] [14] . In agreement with published data, CD14 + monocytes isolated from the same donors studied above ( Figs. 1 and 2) and stimulated in the presence or absence of imiquimod showed an activated phenotype, with upregulation of the expression of the human leukocyte antigen HLA-DR, the costimulatory molecule CD80 and the cytokine receptor CD25 and downregulation of the expression of the costimulatory molecule CD86 (Supplementary Fig. 3a) . Upon being stimulated with imiquimod, CD14 + monocytes also secreted the proinflammatory cytokines IL-6, tumor-necrosis factor and IL-1β and decreased their secretion of IL-10 ( Supplementary Fig. 3b ), whereas we observed no effect on monocyte proliferation (data not shown); this suggested that stimulation of CD4 + T cells and CD14 + monocytes with imiquimod led to completely different outcomes.
To confirm the specificity of the unresponsive phenotype driven by TLR7 signaling, we stimulated CD4 + T cells with anti-CD3 and anti-CD28 in the presence of shRNA specific for TLR7 or nontargeting shRNA, as a control. After 5 d of culture, we confirmed that the efficiency with which protein and RNA was silenced was >80% (Fig. 2d) . We stimulated shRNA-treated resting CD4 + T cells with with anti-CD3 and anti-CD28 in the presence or absence of imiquimod and measured the secretion of IL-2 and IFN-γ. While CD4 + T cells transduced with nontargeting shRNA showed a decrease in the production of IL-2 and IFN-γ secretion after treatment with imiquimod, this effect was abolished in cells expressing TLR7-specific shRNA (Fig. 2e) , which confirmed that the unresponsive state of T cells observed in the presence of imiquimod was TLR7 specific.
Induction of calcium-NFATc2-driven CD4 + T cell anergy by TLR7 The inhibition of the proliferation, cytokine secretion and activation of CD4 + T cells upon stimulation in the presence of TLR7 ligands npg A r t i c l e s resembled the unresponsive phenotype that characterizes clonal anergy 15 . Various model systems have been used to induce clonal anergy, including treatment with the calcium ionophore ionomycin 16, 17 , and the activation of calcium signaling in the absence of activating signals in costimulatory signaling pathways is common in all these models. Thus, the main characteristic of an stimulus that elicits anergy is its ability to induce an unopposed increase in intracellular calcium concentrations 17 . To test the hypothesis that TLR7 signaling on CD4 + T cells was inducing clonal anergy, we stained sorted CD4 + T cells with the ratiometric calcium indicator Indo-1 AM and treated them with various doses of imiquimod (Fig. 3a) .
Imiquimod induced a significant and sustained (maintained for at least 20 min) increase in intracellular calcium concentration in a dose-dependent manner that was TLR7 specific, as blocking TLR7 with IRS 661, a specific inhibitory oligonucleotide sequence 18 , impaired the increase in calcium concentration upon stimulation with imiquimod ( Fig. 3b and Supplementary Fig. 4a ). We did not observe that increase in intracellular calcium concentration in cells stimulated with the TLR8 agonist ssRNA40 or with ligands of other intracellular TLRs, such as the synthetic RNA duplex poly(I:C) (for TLR3) or ODN2006 (for TLR9) ( Fig. 3a and Supplementary  Fig. 4b ). As a positive control, we treated cells with the calcium ionophore ionomycin, which has been used as an anergy-inducing agent in in vitro experiments 17, 19 , and obtained concentrations of intracellular calcium similar to those induced by 10 µg/ml of imiquimod ( Fig. 3a and Supplementary Fig. 4a ).
An immediate consequence of an increase in the concentration of intracellular calcium is the activation of NFATc2, a transcription factor that is highly phosphorylated in resting cells and becomes dephosphorylated by the calcium-calmodulin-dependent phosphatase calcineurin when the concentration of intracellular calcium is increased 20, 21 . To determine whether stimulation with imiquimod induced dephosphorylation of NFATc2, we stimulated CD4 + T cells with imiquimod and purified total protein extracts 0, 45 and 90 min later. Immunoblot analysis with anti-NFATc2 showed that treatment with imiquimod resulted in dephosphorylation of NFATc2; we confirmed these results by analysis of total extracts of CD4 + T cells stimulated for 40 min with imiquimod and probed with a phosphorylation-specific antibody to NFATc2 (Fig. 3c) .
After being dephosphorylated, NFATc2 translocates to the nucleus, where it becomes transcriptionally active 22 . We used nuclear and cytoplasmic protein extracts to further confirm translocation of NFATc2 from the cytoplasm to the nucleus upon stimulation with imiquimod (data not shown). This translocation of NFATc2 to the nucleus in the absence of a concomitant costimulatory signal leads to the transcription of a set of NFATc2-dependent, anergy-related genes that are different from those upregulated with full activation in the presence of a costimulatory signal 17 . To investigate whether stimulation of TLR7 and subsequent dephosphorylation of NFATc2 induce the expression of anergy-related genes 17 , we incubated CD4 + T cells for 2-16 h with imiquimod in the presence or absence of the TLR7-inhibitory sequence IRS 661 and isolated RNA for analysis. As a control for the expression of anergy-related genes, we incubated CD4 + T cells with either ionomycin plus the phorbol ester PMA (a non-anergic stimulus) or ionomycin alone (an anergic stimulus) 17 ( Supplementary Fig. 5 ). Ten of the twelve anergy-related genes examined were significantly upregulated in cells stimulated with imiquimod relative to their expression in the control cells stimulated with vehicle ( Fig. 3d and Supplementary Fig. 5 ). The effect observed in the regulation of these genes was TLR7 specific, as preincubation of CD4 + T cells with IRS 661 before treatment with imiquimod abrogated the increase in the expression of anergy-related genes (Fig. 3d) . Furthermore, we also assessed the expression of other genes encoding molecules that have been functionally related to establishment and maintenance of the anergic phenotype and are targets of NFAT, such as SIRT1 (ref. 23) , ITCH 24 , CBLB 24, 25 , DGKA 26 , EGR2 and EGR3 (ref. 27) , and found that all of these but EGR2 showed significant upregulation upon treatment with imiquimod ( Fig. 3d) . Our data suggested that imiquimod induced clonal anergy in CD4 + T cells via an increase in intracellular calcium concentration and activation of an NFATc2-dependent anergy-related gene-expression program. To further investigate the role of NFATc2 in TLR7-induced T cell anergy, we used two shRNAs to silence NFATC2 and used imiquimod to induce anergy in resting CD4 + T cells after knockdown of NFATc2. After 3 d npg in culture, cells transduced with nontargeting shRNA and stimulated with imiquimod significantly reduced their production of IL-2 and IFN-γ, while cells transduced with NFATC2-specific shRNA were not affected by treatment with imiquimod ( Fig. 3e and Supplementary Fig. 6 ); this suggested that NFATc2 was necessary for the anergic phenotype driven by TLR7 signaling in CD4 + T cells. Treatment with imiquimod did not have an effect on the expression of NFATC2 (Supplementary Fig. 6a ). In agreement with those data and published observations 17 , treatment with imiquimod failed to upregulate the expression of anergy-related genes (KMD6B, IKZF1, GRG4 and RAB10) in CD4 + T cells in which NFATc2 was knocked down relative to their expression in cells transduced with nontargeting shRNA (Supplementary Fig. 6b ), which confirmed that this gene-expression program driven by treatment of CD4 + T cells with imiquimod was largely NFATc2 dependent.
As reported in published studies of an ionomycin-induced anergy model 17 , we hypothesized that pretreatment of CD4 + T cells with imiquimod would be sufficient to diminish their subsequent cytokine secretion and proliferative response to stimulation with both crosslinking of the TCR and costimulatory signaling through CD28. We pretreated memory CD4 + T cells for 2 h with imiquimod in the presence or absence of the inhibitory sequence IRS 661 and allowed them to 'rest' for 12 h after washout to remove all traces of imiquimod and then stimulated the cells for 3 d with anti-CD3 and anti-CD28. Cells pretreated with imiquimod showed significantly lower production of both IL-2 and IFN-γ than that of cells pretreated with vehicle (Fig. 3f) . We observed no significant change in cell viability upon pretreatment wtih imiquimod (data not shown). Again, the proanergic effect of imiquimod was prevented by pretreatment with the TLR7 antagonist IRS 661 (Fig. 3f) . These data suggested that imiquimod induced clonal anergy in CD4 + T cells by inducing calciumdependent activation of NFATc2 and subsequent expression of anergyrelated genes.
Effect of TLR7 signaling on costimulatory signals TLR7 signaling has been studied mainly in APCs, in which it is linked to activation of the transcription factors IRF7 and NF-κB and the kinase Jnk through pathways dependent on or independent of the adaptor MyD88 and the kinase IRAK4 (ref. 1). To assess the consequences of TLR7 signaling on CD4 + T cells relative to the consequences of 'conventional' TLR signaling, we isolated CD4 + T cells from healthy donors and stimulated the cells ex vivo with imiquimod, then assessed the phosphorylation status of IRAK4, Jnk, the p65 subunit of NF-κB and the mitogen-activated protein kinase p38 by flow cytometry. In agreement with published reports of other cell types 2, 3, 5 , stimulation of TLR7 with imiquimod induced phosphorylation of IRAK4, NF-κB and p38 at different time points than did treatment with vehicle (Fig. 4) . Preincubation with IRS 661 before stimulation with imiquimod inhibited the phosphorylation of these molecules (Fig. 4) , which suggested that the effect observed was TLR7 specific. Incubation with IRS 661 by itself did not have any effect on protein phosphorylation (data not shown). Engagement of TLR7 decreased the basal levels of phosphorylated Jnk (Fig. 4) . One of the targets phosphorylated by activated Jnk is Jun, a component of AP-1, which is an essential transcription factor involved in costimulatory signal transduction 17 . We hypothesized that inhibition of Jnk activity by imiquimod might explain, at least in part, the anergic phenotype observed in CD4 + T cells after stimulation with imiquimod in the presence of full stimulation of the TCR and costimulatory signaling (Figs. 1 and 2) . To test this hypothesis, we stimulated CD4 + T cells with PMA plus ionomycin in the presence or absence of imiquimod and assessed the phosphorylation status of Jnk and Jun at various time points. We used NF-κB and p38 as positive controls. Although treatment with imiquimod did not produce an additive effect on the phosphorylation of NF-κB with stimulation, imiquimod further increased the phosphorylation of p38 (Fig. 5a) . Of note, upon stimulation with PMA plus ionomycin, the phosphorylation of Jnk was inhibited by imiquimod, and this decrease in Jnk activity was accompanied by a decrease in the phosphorylation of Jun (Fig. 5a) . Moreover, imiquimod decreased the activity of both Jnk and Jun, as measured by phosphorylation after activation (Fig. 5a) , and it decreased JUN expression (Fig. 5b) . These data supported the hypothesis that imiquimod treatment both induced anergy in CD4 + T cells and interfered with costimulatory signaling during T cell stimulation. The decrease in the expression of CD69 and CD137 (both transcriptional targets of AP-1 (refs. 28,29)) observed after stimulation in the presence of imiquimod (Fig. 1f) further supported this hypothesis. induce the state of T cell unresponsiveness that precedes the loss of CD4 + T cells in HIV-1-infected patients 30 . We hypothesized that a virus-CD4 + T cell interaction through TLR7 would be responsible, at least in part, for the anergic phenotype observed in HIV-1-infected CD4 + T cells from patients. First, we isolated CD4 + T cells from four healthy donors, infected the cells in vitro with physiological concentrations (multiplicity of infection, 0.001) of a replication-competent strain of HIV-1 derived from the prototype HIV-1 NL432 virus and tagged with the red fluorescent reporter DsRed (HIV-1 NL-D ) 34, 35 and assessed their ability to produce IL-2 and IFN-γ 7 d after infection.
In agreement with published reports [30] [31] [32] [33] , infection with HIV-1 NL-D markedly diminished the ability of viable CD4 + T cells to produce IL-2 and IFN-γ after 4 h of stimulation with PMA and ionomycin (Supplementary Fig. 7 ). We did not observe this decrease in cytokine secretion only in the bulk T cell population infected with the virus but specifically in HIV-1 NL-D -infected cells, which suggested that direct interaction of the virus with infected CD4 + T cells rendered the CD4 + T cells unresponsive. To test the hypothesis that TLR7 signaling in CD4 + T cells accounted in part for the anergic phenotype after infection with HIV-1, we isolated CD4 + T cells from healthy donors and treated the cells ex vivo with either of two shRNAs specific for TLR7 (clone 3 or 4), to silence TLR7, or with nontargeting shRNA, as a control (Fig. 6) . After 2 d, we infected the shRNA-treated CD4 + T cells with concentrations of HIV-1 NL-D within the physiological range 34 (multiplicity of infection, 0.001) and measured the frequency of infected cells as well as their ability to produce proinflammatory cytokines every 48 h for a total of 11 d. Although CD4 + T cells transduced with nontargeting shRNA were infected with HIV-1 NL-D to an extent similar to that of untransduced cells, cell populations transduced with TLR7-specific shRNA had a much lower frequency of HIV-1 NL-D -infected CD4 + T cells at all time points examined (Fig. 6a,b) . This lower frequency of HIV-1 + cells was not due to a specific increase in the death of cells in which TLR7 was silenced, as there was no difference between cell populations transduced with TLR7-specific shRNA and control cell populations transduced with nontargeting shRNA in terms of the frequency of early or late apoptotic CD4 + T cells after infection ( Supplementary  Fig. 8 ). We further confirmed the role of TLR7 in decreasing the HIV-1 NL-D infection rate by blockade of TLR7 on CD4 + T cells from healthy donors with various doses of IRS 661 before in vitro infection (Fig. 6c,d) . Moreover, the secretion of cytokines by HIV-1 NL-D -infected cells was significantly different for cells transduced with nontargeting shRNA and their counterparts transduced with TLR7-specific shRNA (Fig. 6e,f) . Although HIV-1 NL-D -infected cells in cultures of CD4 + T cells transduced with nontargeting shRNA produced less IL-2 and IFN-γ protein than did mock-infected CD4 + T cells, the low frequency of HIV-1 NL-D -infected CD4 + T cells transduced with TLR7-specific shRNA secreted significantly more IL-2 and IFN-γ than did their counterparts transduced with nontargeting shRNA (Fig. 6e,f) , which suggested that the anergic phenotype did not develop after infection in cells transduced with TLR7-specific shRNA. To confirm that observation, we assessed the expression of anergy-related genes in CD4 + T cells obtained from healthy donors, infected with HIV-1 NL-D in vitro in the presence of IRS 661 (to inhibit TLR7) or a control sequence and assessed at day 7 after infection. Sorted HIV-1 NL-D + CD4 + T cells showed higher expression of eight of the twelve anergy-related genes examined than did HIV-1 NL-D -CD4 + T cells, while HIV-1 + CD4 + T cells sorted from IRS 661-treated cultures did not upregulate any of these genes at the time point analyzed (Fig. 6g) . The expression of other genes encoding molecules that have been functionally linked to anergy, such as ITCH, DGKA, CBLB and SIRT1, was also upregulated in HIV-1 NL-D + CD4 + T cells but not in IRS 661-treated HIV-1 NL-D + T cells (data not shown). These data suggested that an interaction of HIV-1 NL-D with TLR7 was responsible, at least in part, for the anergic phenotype observed in HIV-1 NL-Dinfected CD4 + T cells.
We investigated the role of the intracellular calcium-and NFATc2-activated gene-expression signaling events we observed by engagement of TLR7 with imiquimod, after infection with HIV-1 NL-D in vitro. We hypothesized that blockade of intracellular calcium and silencing of NFATC2 would lead to a decrease in the frequency of HIV-1 + T cells even in the presence of a functional TLR7. To induce (Fig. 6h) , perhaps due to the essential role of calcium in many cellular processes. Nevertheless, there was a lower frequency of HIV-1 NL-D + T cells among the remaining viable CD4 + T cells in cultures treated with Quin-2 AM than among CD4 + T cells treated with vehicle alone (Fig. 6h) , in agreement with published investigations suggesting a role for calcium in the HIV-1 life cycle 37 . We then silenced NFATC2 with either of two different shRNAs or blocked NFATc2 with VIVIT peptide, which interferes with the calcineurin-NFATc2 interaction and inhibits dephosphorylation of NFAT 38 . In both cases, the absence of functional NFATc2 led to a significantly lower frequency of HIV-1 NL-D -infected T cells than among CD4 + T cells left untreated or treated with vehicle alone (Fig. 6i,j) , which indicated a role for NFATc2 in HIV-1 infection, as previously suggested 39 . These data suggested that calcium-dependent activation of NFATc2 upon triggering of TLR7 was involved in HIV-1 NL-D infection in vitro.
Calcium-induced anergy favors HIV-1 replication
Given the decreased infection rate of cells in which TLR7 was silenced and the non-anergic phenotype of infected CD4 + T cells in which TLR7 was silenced, we hypothesized that the anergic state induced by stimulation via TLR7 during infection with HIV-1 would be a necessary step for HIV-1 to replicate in the host. In the absence of signaling via TLR7, the virus would not be able to render the infecting cell anergic and long-term infection would not occur. To test this hypothesis, we obtained CD4 + T cells from healthy donors, induced anergy in the cells via the TLR7 pathway with various doses of imiquimod and subsequently infected them with HIV-1 NL-D and analyzed them 7 d later. Of note, the frequency of HIV-1 NL-D -infected CD4 + T cells directly correlated with the concentration of imiquimod used and the increase in intracellular calcium (Fig. 7a,b) , and thus with the degree of anergy in the culture, which suggested that calcium-induced anergy favored infection with HIV-1. Moreover, the induction of anergy via other well-established in vitro methods, such as treatment with ionomycin (Fig. 7c,d) or stimulation with anti-CD3 without costimulatory signals (Fig. 7e,f (Fig. 7g) . This further supported the hypothesis that HIV-1-induced anergy was necessary for productive infection with HIV-1.
Inhibition of TLR7 diminishes HIV-1 in T cells ex vivo
We next sought to directly investigate the role of TLR7 in CD4 + T cells from HIV-1-infected patients. Specifically, on the basis of the in vitro model system with HIV-1 NL-D , we hypothesized that inhibition of the TLR7 pathway in CD4 + T cells from HIV-1-infected patients would decrease the infection rate. We isolated CD4 + T cells from HIV-1 infected patients (Supplementary Table 1 ) and stimulated the cells in the presence of IRS 661 or transduced them with either of two TLR7-specific shRNAs, then collected supernatants every 3 d for a total of 14 d to measure virus concentration by ELISA of the HIV-1 core antigen p24. The inhibition of TLR7 by IRS 661 substantially decreased the concentration of p24 in culture (Fig. 8a,b) , and we obtained similar results for cells transduced with TLR7-specific shRNA (Fig. 8c,d) . We assayed CD4 + T cells from healthy donors in parallel as a negative control but found no detectable p24 at any time point (data not shown). Furthermore, we measured the load of proviral integrated DNA at day 7 after stimulation with anti-CD3 and anti-CD28 in the presence of IRS 661 or a control sequence and after transduction with TLR7-specific or nontargeting shRNA to monitor the cellular viral reservoir. Inhibition of TLR7 by either IRS 661 (Fig. 8e) or knockdown of TLR7 (Fig. 8f) resulted in a significantly lower proviral DNA load than that in control cells. Together these results showed that inhibition of TLR7 signaling was able to diminish the HIV-1 load in infected CD4 + T cells derived from infected patients. TLR signaling has been studied predominantly in APCs, in which engagement of the ligand induces the secretion of proinflammatory cytokines and upregulation of activation molecules [12] [13] [14] . Although TLR signaling in CD4 + T cells has not been studied in depth, the few reports published have demonstrated a positive costimulatory role for TLR signaling 7, 8, 40 . Our results have demonstrated a previously undescribed TLR signaling pathway with an inhibitory effect on T cell proliferation and cytokine secretion. The differences between the phenotypes of monocytes and those of CD4 + T cells upon TLR7 stimulation could be due to the intrinsic differences in activation requirements for each cell population. Although CD4 + T cells need engagement of the TCR and a costimulatory signal to enter cell cycle, CD14 + cells require one signal. Thus, engagement of TLR7 by its ligand is sufficient to induce activation and secretion of proinflammatory cytokines in monocytes, as expected for a cell of the innate immune system. In contrast, stimulation of TLR7 in CD4 + T cells leads to a significant increase in intracellular calcium that in the absence of a costimulatory signal triggers the TLR7-driven anergic program 17 . In this context, our results also showed a decrease in CD4 + T cell proliferation upon stimulation of TLR9, with no effect on IFN-γ secretion and a trend toward increased IL-17 secretion, although this result was not significant. Furthermore, there was no increase in the intracellular calcium concentration when CD4 + T cells were stimulated with CpG B, which suggested that the mechanism by which CpG B modifies CD4 + T cell functionality is not common to ligation of TLR7.
We note that all the ligands we used here were pharmacological agonists of TLR7. We have not been able to find any immunostimulatory RNA specific for human TLR7, which would be a more physiological ligand, as these immunostimulatory RNA sequences are specific for mouse TLR7 but recognize human TLR8 instead. We have overcome this issue through the use of HIV-1 as a potential 'natural' ligand of TLR7. The physiological relevance of our data is suggested by the effect of TLR7 signaling on HIV-1-infected cells. Several reports have highlighted the role of innate sensors in infection with HIV-1, focusing on the function of these molecules in CD4 + T cells that had not been productively infected 41, 42 . Our results add a new layer of complexity to the understanding of the HIV viral life cycle, which needs further investigation, and are in contrast with published data describing the cytoplasmic sensors of viral DNA that trigger cell death by pyroptosis of unproductively infected CD4 + T cells 41, 42 . Moreover, the observations reported here suggest involvement of TLR7 both in the induction of the anergic phenotype observed in HIV-1-infected cells and in increases in the degree of infection of CD4 + T cells, which suggests that TLR7-induced upregulation of calcium is involved in the viral life cycle. In this context, TLR8-dependent activation of NF-κB has been shown to be critical for HIV-1 replication in dendritic cells 43 . Although we did not investigate the role of TLR8 in the infection of CD4 + T cells by HIV-1, it is possible that contributions of both TLR7-driven activation of NF-κB and TLR7-induced anergy have a role in the increased viral load. The observation that anergy favored HIV-1 infection is somewhat paradoxical given existing literature showing that HIV-1 infection is favored in activated CD4 + T cells 11 . We speculate that HIV-1 might trigger TLR7 to induce an increase in intracellular calcium concentrations, which has been suggested to be important for the viral life cycle 37 . Whether the induction of anergy in host cells by HIV-1 infection via TLR7 is a bystander consequence of the increase in intracellular calcium driven by TLR7, and whether this status is beneficial for the host or not, are currently unknown. However, these observations open up a new field of investigation related to the mechanism, kinetics and consequences of the interaction of HIV-1 with the host cell through TLR7.
Although infections are generally regarded as illnesses, mammals are colonized with bacteria and viruses. The 'prime' example of this is bacteria adopted for digestion, although humans are also colonized with common DNA and RNA viruses, including endogenous retroviruses. It has been suggested that these endogenous retroviruses provide an adoptive selective advantage in generating genetic diversity 44 . On the basis of our data here, we speculate that TLR7 might have been co-opted in human CD4 + T cells to co-evolve so that the cells do not enter into the cell cycle in response to endogenous retroviruses, with potential consequences such as leukemia (HTLV-1) and autoimmune diseases. There are examples in the literature showing that certain endogenous retrovirus sequences are upregulated in human autoimmune diseases 45 . Although it will be of interest in future investigations to elucidate precisely when TLR7 is engaged in the life cycle of HIV-1 during infection, these data demonstrate a mechanism by which HIV-1 may avoid elimination by co-opting NFAT-dependent TLR7-induced T cell anergy.
In summary, we have demonstrated a previously unknown role for TLR7 in CD4 + T cell function that is in direct opposition to its role in cells of the innate immune system. Moreover, TLR7 ligands may be used as a means of inducing 'tolerance' on CD4 + T cells in human autoimmune diseases. Finally, our data have demonstrated a novel function for microbial pattern-recognition receptors in the inhibition of immune responses.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cell-culture reagents and antibodies. Cells were cultured in RPMI-1640 media supplemented with 2 nM l-glutamine, 5 mM HEPES, and 100 U/µg/ml penicillin-streptomycin (Biowhittaker), 0.5 mM sodium pyruvate, 0.05 mM nonessential amino acids (Life Technologies) and 5% human AB serum (Gemini Bio-Products). The antibodies used for stimulation were anti-human CD3 (UCHT1 and Hit3a; BD Biosciences) and anti-human CD28 (28.2; BD Biosciences) at 1 µg/ml. The antibody to TLR7 (533707) used for staining was from R&D Systems. IL-2 was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health), and was used at 10 U/ml at the initiation of cultures. All TLR ligands (<0.001 EU/µg; EndoFit) were resuspended in endotoxin-free water according to the manufacturer's recommendations (Invivogen). PMA (phorbol 12-myristate 13-acetate) and Ionomycin were from Sigma-Aldrich. IRS 661, the TLR-specific inhibitory sequence 46 , was synthesized by Sigma-Aldrich on a phosphorothioate backbone.
Study subjects. Peripheral blood was drawn from healthy donors after informed consent was provided and approval was obtained from the Institutional Review Board at Yale University.
HIV-1 + patients. Peripheral blood was obtained from nine HIV-1-infected patients after informed consent was provided and approval was obtained from the Institutional Review Board at Yale University. Patient information is provided in Supplementary Table 1 .
Cell isolation and sorting of T cell populations by flow cytometry.
Peripheral blood mononuclear cells were isolated from healthy donors by Ficoll Hypaque gradient centrifugation. Total CD4 + T cells were isolated by negative selection with CD4 + T cell isolation kit (StemCell Technologies) and were stained for fluorescence-activated cell sorting with the following antibodies: anti-CD45RO (UCHL1), CD45RA (Hl100), CD25 (M-A251; all from BD Biosciences); and CD127 (eBioRDR5; eBioscience). Populations of T reg cells (CD4 + CD25 hi CD127 lo-neg ), memory T cells (CD4 + CD45RA − CD45RO + CD25 low/neg ) and naive T cells (CD4 + CD45RA + CD45RO − CD25 lo-neg ) were sorted on a FACSAria (BD Biosciences). Unless specified otherwise, CD4 + T cell populations used in the experiments were depleted of T reg cells and were sorted as CD4 + CD25 pos-lo CD127 + . CD14 + cells were isolated by positive selection with an EasySep Human CD14 Positive Selection Kit (StemCell Technologies).
Cell activation and intracellular staining. T cell populations were stimulated with 1 µg/ml anti-CD3, 1 µg/ml anti-CD28 and 10 U/ml IL-2 (antibodies identified above) in the presence or absence of the following TLR ligands (all from Invivogen): Pam 3 CSK 4 (0.5 µg/ml; tripalmitoyl cysteinyl seryl tetralysine lipopeptide), heat-killed Listeria monocytogenes (5 × 10 7 cells per ml), poly (I:C) (high molecular weight; 10 µg/ml), ultrapure lipopolysaccharide from Escherichia coli K12 strain (10 µg/ml), recombinant flagellin from Salmonella enterica (0.2 µg/ml), synthetic diacylated lipoprotein (FSL-1; 0.2 µg/ml), imiquimod (0.1-10 µg/ml), gardiquimod (5 µg/ml), loxoribine (1 mM), CL264 (9-benzyl-8 hydroxyadenine; 20 µg/ml), ssRNA40 in LyoVec (0.5 µg/ml) and ODN2006 (2.5 µM). At day 4, cells were stimulated for 4 h with 50 ng/ml phorbol-12-myristate-13-acetate (PMA) and 250 ng/ml ionomycin in the presence of GolgiStop (BD Biosciences) and intracellular staining of cytokines (IFN-γ, IL-10, IL-17, IL-4 and IL-2) and Foxp3 was performed with Foxp3 staining buffers per the manufacturer's recommendations (eBioscience) and the following antibodies: anti-IFN-γ (4S.B3; BioLegend), anti-IL-17 (BL168; BioLegend), anti-IL-10 (JES3-19F1; BD Biosciences), anti-IFN-γ (B27; BD Biosciences), anti-IL-4 (3010.211; BD Biosciences) and anti-Foxp3 (PCH101; eBioscience). For both extracellular staining and intracellular staining, LIVE/DEAD reagent (Molecular Probes) was used to exclude dead cells before surface staining. CD14 + monocytes were cultured for 24 h with various TLR ligands and cell surface staining was performed as described above with an initial FcR-blocking step (FcR blocking reagent, human; Miltenyi Biotech). Samples were run on a BD Fortessa instrument and were analyzed with FlowJo software (TreeStar).
ELISA. IFN-γ, IL-2, IL-17, IL-4 and IL-10 in supernatants of stimulated CD4 + T cell culture and of tumor-necrosis factor, IL-1β and IL-6 in CD14 + cultures were measured with an ELISA kit according to manufacturer's recommendations (BD Biosciences). Antibody pairs for IL-2, IL-17 and IL-10 were from R&D Systems (Quantikine ELISA kits); biotin-labeled monoclonal antibody to IFN-γ ( 2G1) and monoclonal antibody to human IFN-γ (PA1-84955) were from Thermo Scientific; and antibody pairs for IL-10 (JES3-19F1 and JES3-12G8), IL-6 (MQ2-13A5 and MQ2-39C3), tumor-necrosis factor (MAb11 and MAb1) and IL-1β (CRM56 and CRM57) were from BD Biosciences. Immunoblot analysis. Total protein extracts were isolated with an M-PER protein extraction kit (Thermo Scientific) and protein was quantified with a BCA kit (Thermo Scientific). 20 µg of protein extract was loaded in each lane, followed by separation by 10% SDS-PAGE and transfer to a nitrocellulose membrane. Anti-NFAT1 (D43B1) and anti-β-actin (13E5) were from Cell Signaling Technology. Antibody to NFAT phosphorylated at Ser213, Ser217 and Ser229 (sc-32991) was from Santa Cruz Biotechnology. Primary antibodies were detected by the secondary antibody horseradish perixidase-conjugated anti-rabbit (Cell Signaling Technology), and images were obtained with a charge-coupled device camera instrument. Bands were quantified with QuantityOne software.
Quantification
Measurement of intracellular calcium. Isolated CD4 + T cells were labeled ex vivo for 1 h at 37 °C with 5 µM Indo-1 AM in PBS and 1 mM Ca 2+ . Cells were washed to remove traces of Indo-1 AM, then were resuspended in buffer at 1 × 10 6 cells per ml and were incubated for 30 min at 37 °C before analysis. Where necessary, IRS 661 was added at the appropriate concentration during the 30 min of incubation. For acquisition, samples were acquired for approximately 3 min to obtain basal levels of calcium, and subsequently imiquimod or other reagents were added at the appropriate concentrations. Samples were acquired for a minimum of 10 min on a BD Fortessa and were analyzed with FlowJo software.
Gene silencing by lentiviral transduction. Lentiviral particles encoding shRNA were from Sigma-Aldrich (TRCN0000016144 (NFAT1), TRCN0000056973 (TLR7 clone 3) and TRCN0000056974 (TLR7 clone 4)). CD4 + T cells (5 × 10 4 cells per well) were stimulated for 12 h with plate-bound anti-CD3 (1 µg/ml) and soluble anti-CD28 (1 µg/ml) (antibodies identified above) before transduction. Cells were then transduced with viral particles containing a vector expressing shRNA specific for NFAT1 or TLR7, or with nontargeting shRNA as a control, at a multiplicity of infection (MOI) of 4. All constructions contained sequence encoding green fluorescent protein. Preparation of HIV-1 viral stocks. HIV-1 NL-D (HIV-1 proviral DsRed-tagged DNA plasmid pNL-D, derived from the prototype HIV-1 proviral DNA plasmid pNL432) was provided by Y. Tsunetsugu-Yokota. 293T human embryonic kidney cells were used to prepare viral stocks following published protocols 35 with minor modifications. 293T cells were plated at a density of 0.5 × 10 6 cells per well in 12-well plates and were transfected for 48 h with 2 µg pNL-D through the use of Lipofectamine 2000 (Invitrogen). Culture supernatants were treated for 30 min at 37 °C with benzonase (1 U/ml), were cleared by filtration and were 'titrated' on 293T cells. Stocks were stored at -80 °C.
In vitro infection with HIV-1. CD4 + T cells were stimulated for 48 h with anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) (antibodies identified above) and were subsequently infected with HIV-1 at an MOI of 0.001 (a concentration within the physiological range 34 ). Viability and cytokine secretion was measured every 48 h for a total of 11 d after infection.
For infection of TLR7-deficient cells with HIV-1, CD4 + T cells were stimulated anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) (antibodies identified above) and were transduced with the corresponding lentiviral particles. 2 d after transduction, the cells were infected with HIV-1 NL-D at an MOI of 0.001. The viability and frequency of HIV-1-infected cells was measured at various time points by staining with LIVE/DEAD cell dye and fixation with 1% PFA. For intracellular staining after infection, the cells were restimulated for 4 h with PMA and ionomycin in the presence of GolgiStop and were stained as recommended with a Foxp3 staining kit (eBioscience) with a pre-fixation step with 1% PFA to avoid loss of DsRed signal.
DNA proviral load. 50 × 10 3 CD4 + T cells were stimulated as described above anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) (antibodies identified above) and DNA was isolated after 7 d for measurement of the DNA proviral load as published 47 .
T cell clones. CD4 + T cells were sorted at a density of one cell per well in 96-well plates and were stimulated for 18 d with anti-CD3 (1 µg/ml), anti-CD28 (1 µg/ml), IL-2 (25 U/ml) (antibodies identified above) and irradiated peripheral blood mononuclear cell samples (5 × 10 4 cells) depleted of T cells. The medium was replaced every 3 d. After 18 d, clones were stimulated for 3 d with anti-CD3 and anti-CD28 (antibodies identified above) in the presence or absence of imiquimod, and supernatants were collected for ELISA and cells were lysed for isolation of RNA.
Staining to assess apoptosis. CD4 + T cells were stimulated for 48 h with anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) (antibodies identified above) and were subsequently infected with HIV-1 NL-D at an MOI of 0.001. Annexin V (AnnV) and 7-amino-actinomycin D (7-AAD) were used to stain cells every 24 h to assess early apoptosis (AnnV + 7-AAD -) and late apoptosis (7-AAD + ), for a total of 11 d.
Analysis of phosphorylation by flow cytometry. CD4 + T cells were stimulated with 10 µg/ml imiquimod in the presence or absence of 50 ng/ml PMA and 250 ng/ml ionomycin, and the cells were fixed at various time points with Fixation buffer (BD Biosciences), permeabilized with Perm buffer III according to the manufacturer's recommendations (BD Biosciences), and were stained with phycoerythrin-labeled mouse antibody to p38 phosphorylated at Thr180 and Tyr182 (36/p38; BD Biosciences), Alexa Fluor 488-labeled antibody to NF-κB p65 phosphorylated at Ser529 (K10-895.12.50; BD Biosciences), Alexa Fluor 647-labeled antibody to mouse Jnk phosphorylated at Thr183 and Tyr185 (9257S; Cell Signaling), phycoerythrin-labeled rabbit antibody to IRAK4 phosphorylated at Thr345 and Ser346 (D6D7; Cell Signaling) and phycoerythrinlabeled antibody to c-Jun phosphorylated at Ser73 (D47G9; Cell Signaling).
In vitro anergy induction. CD4 + T cells were incubated for 12 h with either 1 µM ionomycin or 0.5 µg/ml plate-bound anti-CD3 (identified above) (or with vehicle as a control), then were washed and then restimulated with anti-CD3 and anti-CD28 (antibodies identified above) after a 6-hour resting period. 2 d later, cells were infected with HIV-1, and the frequency of infected cells was assessed every other day for a total of 11 d.
Statistics. GraphPad Prism software was used for statistical analysis. A standard paired two-tailed t-test was used for statistical analysis and a one-way analysis of variance (ANOVA) with a Tukey's post-test was for comparisons of more than two groups; P values of 0.05 or less were considered significant. 
